Chemotherapy in the belly for pancreatic cancer that has spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy drugs (NALIRIFOX given through a vein plus paclitaxel given directly into the abdomen) for people with pancreatic cancer that has spread to the lining of the belly but not to other organs. The goal is to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your pancreatic cancer must have spread to the lining of your abdomen (peritoneum) but not to other organs.
- You must have been on chemotherapy (FOLFIRINOX or NALIRIFOX) for 0 to 4 months and be able to take more.
- You need to be in fairly good health, able to do daily activities (ECOG 0 or 1).
- Your blood counts, liver, and kidney function must be within a certain range.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This trial tests a treatment called PIPAC, where chemotherapy is sprayed as a mist into the abdomen during a minimally invasive surgery. It is for people whose pancreatic cancer has spread to the lining of the belly, and aims to see if this approach is safe and helpful.
This trial tests a combination of chemotherapy drugs (liposomal irinotecan with fluorouracil, leucovorin, and oxaliplatin) given before and after surgery for pancreatic cancer that can be fully removed. It aims to see if this approach improves outcomes for patients with stage I or II disease.
This study looks at two treatment approaches for pancreatic cancer. In the first part, a new drug combo called NALIRIFOX is given as the first treatment. In the second part, researchers test whether a special antibiotic can make a common chemo work better by targeting gut bacteria.
This trial tests a combination of standard chemotherapy, MRI-guided radiation, and surgery for people with locally advanced pancreatic cancer that might be removable. The goal is to see if this approach can make more tumors resectable.
This trial tests a combination of three drugs (gemcitabine, erlotinib, and nab-paclitaxel) for people with a specific type of pancreatic cancer called 'basal-like' PDAC. It aims to see if this targeted approach works better than standard treatment.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.